0001178913-20-001842.txt : 20200619 0001178913-20-001842.hdr.sgml : 20200619 20200619070014 ACCESSION NUMBER: 0001178913-20-001842 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200619 FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMode Ltd. CENTRAL INDEX KEY: 0001742692 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39016 FILM NUMBER: 20974259 BUSINESS ADDRESS: STREET 1: TAVOR BUILDING, SHA?AR YOKNEAM STREET 2: POB 533 CITY: YOKNEAM STATE: L3 ZIP: 2069200 BUSINESS PHONE: 972-4-9097470 MAIL ADDRESS: STREET 1: TAVOR BUILDING, SHA?AR YOKNEAM STREET 2: POB 533 CITY: YOKNEAM STATE: L3 ZIP: 2069200 6-K 1 zk2024563.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13In a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2020

INMODE LTD.
(Exact name of registrant as specified in its charter)

Tavor Building, Sha’ar Yokneam
P.O. Box 533
Yokneam 2069206 Israel
 (Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐ No ☒


Further to its Current Report on Form 6-K, dated May 11, 2020, InMode Ltd. (the “Company”) announces the following results of its Special General Meeting of Shareholders (the “Meeting”), which was held on June 16, 2020:


 •
In respect of Proposal 1 – The required majority of shareholders represented at the Meeting voted to ratify and approve the re-pricing of certain options previously granted by the Company on November 25, 2019, January 7, 2020, January 28, 2020 and February 17, 2020 to U.S. participants (except for such grants to executive officers as set out in Proposals 2, 3 and 4 in the Company’s proxy statement dated May 11, 2020), by way of cancellation and re-grant of such options under the same terms and conditions as originally granted (including the same vesting schedule) but with a lower exercise price of US $19.69, as previously approved by the Company's compensation committee (the “Compensation Committee”) and board of directors (the “Board”) on March 15, 2020.


•
In respect of Proposal 2 – The required majority of shareholders represented at the Meeting voted to ratify and approve the re-pricing of 90,000 options previously granted on January 7, 2020 by the Company to the Company's executive officer, Mr. Shakil Lakhani (President – North America), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price of $19.69, as previously approved by the Compensation Committee and Board on March 15, 2020.


•
In respect of Proposal 3 – The required majority of shareholders represented at the Meeting voted to ratify and approve the re-pricing of 20,000 options previously granted on January 7, 2020 by the Company to the Company's executive officer, Mr. Yair Malca (Chief Financial Officer), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price of $19.69, as previously approved by the Compensation Committee and Board on March 15, 2020.


•
In respect of Proposal 4 – The required majority of shareholders represented at the Meeting voted to ratify and approve the re-pricing of 90,000 options previously granted on January 7, 2020 by the Company to the Company's executive officer, Dr. Spero Theodorou (Chief Medical Officer), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price of $19.69, as previously approved by the Compensation Committee and Board on March 15, 2020.

This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933, as amended.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
InMode Ltd.
   
 
By: /s/ Moshe Mizrahy

Moshe Mizrahy
 
Chief Executive Officer and Chairman of
The Board of Directors

Dated June 19, 2020